Grant: Catalyst Grant: Bioinformatics Approaches to Cancer Research
University of British Columbia
$99,078.00
Improving computational inference of single nucleotide variants from next generation sequencing of cancer genomes.
FY 2008-09
Summary
Genetic alterations are a key underlying cause of cancer. Recent developments in DNA sequencing technology (called next generation sequencing) now allow us to look for genetic alterations in tumours at unprecedented resolution. This will advance our understanding of the molecular mechanisms of tumour formation, and provide us with new diagnostic and therapeutic drug targets. Moreover, we expect that the new technology will reveal the reason why so many types of cancers have distinct subtypes, each with a different response to therapy. Identifying the genetic alterations that dictate how tumours respond to therapy will help physicians to make better decisions about how to treat each individual patient.
Next generation sequencing produces vast amounts of data that must be interpreted computationally. We have now sequenced 17 ovarian cancers, from 6 distinct subtypes, and 1 breast cancer. Using current state-of-the-art computational tools to infer genetic alterations from these data has already yielded important discoveries. However, the current methods have also thrown up numerous false predictions of genetic alterations that do not validate upon further sequence analysis. Furthermore, since this technology is so new, the scientific community does not yet know whether important alterations that may be present in the data are being missed by current computational techniques.
Our aim is to improve the current standard of computational analysis to more accurately infer the genetic alterations present in next generation sequencing data from tumour DNA. We plan to study the nature of false and missed predictions, and develop new statistical models that will outperform the current state-of-the-art tools. This will allow us to fully capitalize on the unprecedented richness of next generation sequencing data. Ultimately this is the knowledge that will lead to improved clinical management of cancers and result in improved outcomes for those afflicted with cancer.
Department
Program
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
182345
Name
Aparicio Samuel J
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Projecttitle
Improving computational inference of single nucleotide variants from next generation sequencing of cancer genomes.
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$99,078
Cihrequipment2
$0
Programname2
Catalyst Grant: Bioinformatics Approaches to Cancer Research
Keyworddelim
Bayesian Statistics; Next Generation Sequencing Data; Probabilistic Inference; Sequence Alignment; Single Nucleotide Variants; Statistical Modeling
Abstract
Genetic alterations are a key underlying cause of cancer. Recent developments in DNA sequencing technology (called next generation sequencing) now allow us to look for genetic alterations in tumours at unprecedented resolution. This will advance our understanding of the molecular mechanisms of tumour formation, and provide us with new diagnostic and therapeutic drug targets. Moreover, we expect that the new technology will reveal the reason why so many types of cancers have distinct subtypes, each with a different response to therapy. Identifying the genetic alterations that dictate how tumours respond to therapy will help physicians to make better decisions about how to treat each individual patient.
Next generation sequencing produces vast amounts of data that must be interpreted computationally. We have now sequenced 17 ovarian cancers, from 6 distinct subtypes, and 1 breast cancer. Using current state-of-the-art computational tools to infer genetic alterations from these data has already yielded important discoveries. However, the current methods have also thrown up numerous false predictions of genetic alterations that do not validate upon further sequence analysis. Furthermore, since this technology is so new, the scientific community does not yet know whether important alterations that may be present in the data are being missed by current computational techniques.
Our aim is to improve the current standard of computational analysis to more accurately infer the genetic alterations present in next generation sequencing data from tumour DNA. We plan to study the nature of false and missed predictions, and develop new statistical models that will outperform the current state-of-the-art tools. This will allow us to fully capitalize on the unprecedented richness of next generation sequencing data. Ultimately this is the knowledge that will lead to improved clinical management of cancers and result in improved outcomes for those afflicted with cancer.
Competitiondate
200903
Approvedterm2
1 yr 0 mth
Pinamesdelim
Aparicio, Samuel J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $99,078~ $0~